Bimekizumab improves pain, morning stiffness, and fatigue in axial spondyloarthritis patients, with sustained benefits over a ...
The risk for recurrent cardiovascular events is high among patients with r-axSpA and a history of these events, though TNF inhibitor therapy may offer protective benefits.
AxSpA can bring on plantar fasciitis, which is when inflammation in the heel causes the sole of your foot to hurt. You may ...
Alcohol consumption was associated with lower levels of axSpA disease activity and spinal pain, but may be linked to ...
TNF inhibitors offered greater protection against fractures than NSAIDs in patients with axial spondyloarthritis (axSpA).
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...
Study finds TNF inhibitors lower hip and spine fracture risk in axial spondyloarthritis, addressing inflammation-related ...
High-dose nonsteroidal anti-inflammatory drug use among patients with axial spondyloarthritis (axSpA) may not increase the risk of developing hypertension, according to study results presented at the ...
ACELYRIN, INC. (SLRN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vikram ...
The following is a summary of “Association of Therapies for Axial Spondyloarthritis on the Risk of Hip and Spine Fractures,” published in the December 2024 issue of Rheumatology by Driscoll et al.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback